Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
STOCKHOLM, June 26, 2026 /PRNewswire/ –The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical safety or efficacy concerns were identified that impact approvability Sobi to meet with FDA…
News provided by PR Newswire.
